News >

Rituximab/Lenalidomide Regimen Misses Endpoint in Phase III Follicular Lymphoma Study

Silas Inman @silasinman
Published: Friday, Dec 22, 2017

Gilles A. Salles, MD, PhD
Gilles A. Salles, MD, PhD
The combination of rituximab (Rituxan) and lenalidomide (Revlimid) followed by maintenance therapy with the same regimen did not improve response nor progression-free survival (PFS) compared with rituximab and chemotherapy with rituximab maintenance for patients with previously untreated follicular lymphoma.

The phase III AUGMENT trial is currently assessing R2 versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma. The trial is including those with grade 1, 2, or 3a follicular lymphoma or MZL. The primary endpoint of the study, which has enrolled 357 patients, is PFS. Results from the study are anticipated soon (NCT01938001).
Coleman M, Andorsky DJ, Yacoub A, et al. Phase IIIB study of lenalidomide plus rituximab followed by maintenance in relapsed or refractory NHL: analysis of marginal zone lymphoma. Presented at: 14th International Conference on Malignant Lymphoma; June 14-17, 2017; Lugano, Switzerland. Abstract 139. DOI: 10.1002/hon.2437_138.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Archived Version of a Live Webcast: Virtual Current Trends™: European Perspectives on the Advancing Role of CAR T-Cell Therapy in Hematologic MalignanciesJun 29, 20192.0
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Publication Bottom Border
Border Publication
x